Tag: GlobeNewswire

HOUSTON, Oct. 07, 2026 (GLOBE NEWSWIRE) — Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin” or the “Company”) today announced that it will present at the upcoming 2026 Maxim Growth Summit in New York, NY. Details of the presentation are as follows:

Session: Advances in Oncology Panel
Presenter: Walter Klemp, Chairman and Chief Executive Officer of Moleculin
Date/time: Wednesday, October 14, 2026, from 9:00 – 10:00 a.m. ET
Location: NYY Room at the Hard Rock Hotel NYC

Mr. Klemp will discuss Moleculin’s oncology pipeline and recent clinical progress, including the Company’s lead investigational candidate, Annamycin, and its ongoing Phase 2/3 MIRACLE clinical trial evaluating Annamycin in combination with cytarabine (AnnAraC) for the treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML). Moleculin recently announced that Part A enrollment is completed in the MIRACLE trial, and the Company remains on track for its planned comprehensive data readout of Part A in the first quarter of 2027.

In addition to the Company’s presentation, management will be available for meetings with institutional investors in one-on-one sessions.

This prestigious event brings together industry leaders, innovators, and premier institutions to explore the latest trends and advancements across several industries. For more information and a complete agenda of the Maxim Growth Summit, please visit www.maximgrp.com/2026-growth-summit

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company’s lead program, Annamycin (also known as naxtarubicin), has shown to be an efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

The Company is conducting the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design, multi-center, randomized, double-blind, placebo-controlled Phase 2/3 trial evaluating Annamycin in combination with cytarabine (also referred to as “Ara-C”), together referred to as AnnAraC, for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway toward a potential approval for Annamycin for the treatment of AML. This study remains subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.

Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin also has in its pipeline a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications.

For more information about the Company, please visit www.moleculin.com and connect on X, LinkedIn and Facebook.

Forward-Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the potential efficacy and safety of Annamycin and AnnAraC in R/R AML, expected timing of the comprehensive Part A data readout in Q1 2027, the anticipated composition of the Part A population including the expected approximate 50/50 split between fit and unfit subjects, the potential for Part A data to support dose selection for Part B, and the expectation that interim efficacy trends observed in a limited patient population will be confirmed in the full study population. Moleculin will require significant additional financing, for which the Company has no commitments, in order to conduct its clinical trials as described in this press release, and the milestones described in this press release assume the Company’s ability to secure such financing on a timely basis. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company relies on the reports of its expert with regard to the absence of cardiotoxicity. The dataset referenced in this press release is subject to the review of the data from future subjects in its current and future clinical trials and long-term follow-up with subjects in its current trials. Moleculin has attempted to identify forward-looking statements by terminology including ‘believes,’ ‘estimates,’ ‘anticipates,’ ‘expects,’ ‘plans,’ ‘projects,’ ‘intends,’ ‘potential,’ ‘may,’ ‘could,’ ‘might,’ ‘will,’ ‘should,’ ‘approximately’ or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. “Risk Factors” in our most recently filed Form 10-K filed with the Securities and Exchange Commission (SEC) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
MBRX@jtcir.com

Advanced Grid Reliability Offerings Help Utilities Reduce Outage Duration and Prevent Grid Failures Before Customers Are Impacted 

• Advanced Grid Reliability bundles reduce outage duration through faster detection, response and restoration
• Early fault detection helps to prevent outages before customers are affected
• Existing advanced metering infrastructure becomes a source of grid intelligence without deploying new field sensors

LIBERTY LAKE, Wash., Oct. 07, 2026 (GLOBE NEWSWIRE) — Itron, Inc. (NASDAQ: ITRI), the intelligent infrastructure provider for modern energy and water management, announced today the expansion of its Advanced Grid Reliability (AGR) solution to include two new solution bundles: Outage Awareness and Fault Prevention.

Now commercially available in North America, the bundles are designed to help utilities prevent outages, restore power faster, deliver more reliable, affordable service to customers and improve grid performance using advanced metering infrastructure (AMI) 2.0 grid edge intelligence. With Grid Edge Intelligence (GEI), the solutions convert rich grid sensing from across the distribution system into actionable operational intelligence.

Built on Itron’s AMI 2.0 grid edge intelligence portfolio, AGR has demonstrated measurable improvements in outage duration, outage frequency and operational efficiency across multiple customer validation projects.

Customer validations have shown reliability improvements ranging from 6 to 12 minutes of SAIDI, representing an 8% to 15% improvement for utilities with annual outage durations of 75 to 80 minutes. Based on industry-accepted economic impact models, a North American utility serving 1 million customers could realize an estimated $40 million to $90 million in annual business value through shorter outages, fewer interruptions and more efficient grid operations.

Most large electric utilities have already installed smart meters across their service territories, primarily for the purposes of billing and meter data collection. Itron’s AGR solution helps extract greater value from existing infrastructure by enabling smart meters to serve as intelligent grid sensors. With this intelligence, utilities can detect, diagnose and respond to costly performance issues faster.

Itron’s AGR solution integrates high-resolution AMI 2.0 meter data and near real-time low voltage sensor data with utility operational systems through Itron’s Intelligent Edge Operating System (IEOS). Back-office analytics engines identify fault precursors and grid anomalies. IEOS then delivers these insights directly to Advanced Distribution Management Systems (ADMS), Outage Management Systems (OMS), Global Information Systems (GIS) and enterprise asset management workflows, enabling operators to act upon issues earlier, locate them more accurately and restore service faster. By combining edge sensing with advanced analytics, AGR helps utilities move from reacting to grid events to understanding their cause, predicting potential impacts and taking action sooner.

Find Outages Faster with Outage Awareness

The Outage Awareness bundle helps utilities reduce outage duration by providing near real-time visibility into outage conditions across the distribution grid. Outage Awareness analyzes data from smart meters and across the network, enabling utilities to quickly understand where outages are occurring, how many customers are affected and when service has been restored. This provides a more complete picture of grid conditions, helping work crews respond faster and reduce time spent locating faults.

Prevent Outages Altogether with Fault Prevention

The Fault Prevention bundle helps utilities identify potential equipment problems before they lead to outages. Using smart meter data, on-meter anomaly detection and advanced fault analytics, the solution can detect unusual electrical activity and other early warning signs that may indicate a developing issue, while pinpointing where on the grid it is occurring. This enables utilities to take proactive maintenance actions before customers are affected, reducing the frequency of unplanned outages and improving overall system reliability and customer satisfaction.

The Fault Prevention and Outage Awareness bundles expand upon the existing Grid Awareness solution within AGR. While each bundle delivers value independently, the greatest benefits are realized when all three work together. When combined the three applications provide a more complete view of grid operations, helping utilities strengthen reliability, improve operational efficiency and deliver better, more affordable service to customers

The AGR solution is pre-integrated with leading advanced distribution management system platforms and supports other utility-selected data lake solutions through Itron’s IEOS platform.

“Itron’s AGR solution helps utilities use AMI 2.0 to improve reliability, prevent outages and operate the grid more effectively,” said Don Reeves, senior vice president of Outcomes at Itron. ” By combining edge intelligence, advanced analytics and operational workflows, utilities can move beyond reacting to grid failures and begin predicting and preventing them. When outages do occur, AGR helps utilities detect issues faster, respond more effectively and improve service reliability for customers.”

About Itron

Itron is transforming how the world manages energy, water and city services. Our trusted intelligent infrastructure solutions help utilities and cities improve efficiency, build resilience and deliver safe, reliable and affordable service. With edge intelligence, we connect people, data insights and devices so communities can better manage the essential resources they rely on to live and thrive. Join us as we create a more resourceful world: www.itron.com.

Itron^® and the Itron Logo registered trademarks of Itron, Inc in the United States and other countries and regions. All third-party trademarks are property of their respective owners and any usage herein does not suggest or imply any relationship between Itron and the third party unless expressly stated.

For additional information, contact:

Itron, Inc.

Alison Mallahan
Senior Manager, Corporate Communications
509-891-3802
PR@Itron.com

Paul Vincent
Vice President, Investor Relations
512-560-1172
Investors@itron.com

Itron, Inc.

• LinkedIn: www.linkedin.com/company/itroninc
• X: www.x.com/itroninc
• Newsroom: https://itron.com/newsroom
• Blog: https://itron.com/blog

LAS VEGAS, NEVADA, Oct. 07, 2026 (GLOBE NEWSWIRE) — Avaí Bio, Inc. (OTCQB: AVAI) (“Avaí” or the “Company”) and its joint venture partner Austrianova, today announced the first joint steering committee meeting for their collaboration with Ospedale San Raffaele S.r.l. (OSR), to discuss the initial research program for evaluating an encapsulated beta-cell replacement approach for insulin-dependent diabetes.

The meeting brought together Prof. Lorenzo Piemonti, Director of the Diabetes Research Institute at OSR, and Dr. Valeria Sordi, Head of the Beta Cell Differentiation Unit, together with Austrianova’s Prof. Walter H. Gunzburg and Dr. Brian Salmons, and Dr. Eva Maria (Lilli) Brandtner, consultant to Insulinova and staff researcher at the Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT).

Avaí Bio and Austrianova established Insulinova as an equally owned joint venture to explore encapsulated cell-based therapies for diabetes. Under the collaboration with OSR, the partners will evaluate the encapsulation of OSR’s stem cell-derived beta cells using Austrianova’s Cell-in-a-Box^® technology.

The initial work will focus on determining whether encapsulated beta cells can maintain viability and function. These studies are intended to provide the experimental basis for assessing whether the encapsulation platform can support beta-cell viability and function, and, subsequently, whether it may offer a strategy to improve immune protection of transplanted cells.

“This first meeting allowed the teams to align on the experimental program and the initial development priorities,” said Chris Winter, Chief Executive Officer of Avaí Bio. “The collaboration combines Ospedale San Raffaele’s expertise in stem cell-derived beta-cell differentiation and beta-cell replacement with Austrianova’s cell encapsulation platform, and the next step is to generate the data needed to assess how the two technologies perform together.”

Dr. Brian Salmons, Chief Executive Officer of Austrianova, added, “Cell encapsulation has long been investigated as a potential strategy to protect therapeutic cells following transplantation. This collaboration gives us the opportunity to evaluate our Cell-in-a-Box^® technology with stem cell-derived beta cells in a structured experimental program, and to determine whether the approach warrants further development.”

“Beta-cell replacement represents an important therapeutic strategy for diabetes, but significant challenges remain, particularly in protecting transplanted cells from the immune system,” said Prof. Lorenzo Piemonti, Director of the Diabetes Research Institute at Ospedale San Raffaele. “This collaboration allows us to evaluate Austrianova’s encapsulation technology using our stem cell-derived beta-cell platform. We are at an early stage, and the immediate priority is to establish whether the approach can preserve beta-cell viability and function under well-controlled experimental conditions. These data will determine how, and whether, the program should progress toward further development.”

About Avaí Bio, Inc.
Avaí Bio, Inc. is an emerging biotechnology company focused on identifying genetically modified cell lines, and through joint venture and licensing agreements developing innovative cell-based therapies.

About Austrianova (SGAustria Pte. Ltd.)
Austrianova, based in Singapore, is a leading biotechnology company specializing in cell encapsulation, GMP-grade cell products, and cell line development, backed by over 50 peer-reviewed publications and partnerships with global pharmaceutical and biotech companies.

About Ospedale San Raffaele
San Raffaele Hospital, part of the San Donato Group, is a university hospital and internationally renowned research institute with highly specialized expertise in the diagnosis and treatment of several major diseases. Founded in 1971 and recognized in 1972 as a Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), it serves as a Highly Specialized Emergency Center (E.A.S.) and as the teaching hospital of Vita-Salute San Raffaele University.

The IRCCS San Raffaele Hospital is accredited by the Italian National Health Service and offers more than 60 clinical specialties. Its multidisciplinary organization integrates scientific research, education, and clinical practice to support the study and treatment of diseases and the development of new therapies.

More information about Avaí Bio can be found at https://www.avaibio.com
More information about Austrianova can be found at https://austrianova.com
More information about OSR can be found at www.hsr.it

You can also follow us on social media at:

https://x.com/AvaiBio
https://facebook.com/AvaiBio
https://youtube.com/@AvaiBio
https://facebook.com/Austrianova

Forward-Looking Statements
Certain statements contained in this press release may constitute “forward-looking statements.”  Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact.  Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov).  In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company’s ability to raise capital on acceptable terms, if at all, the Company’s successful development of its products and the integration into its existing products and the commercial acceptance of the Company’s products.  The forward-looking statements included in this press release represent the Company’s views as of the date of this press release and these views could change.  However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.  These forward-looking statements should not be relied upon as representing the Company’s views as of any date after the date of the press release.

CONTACT: Avaí Bio, Inc.
info@avaibio.com

Renewal extends a long-standing relationship with a key Dutch government agency through April 2030 and expands Circle8’s multi-year public-sector contract base.

ENGLEWOOD CLIFFS, N.J., Oct. 07, 2026 (GLOBE NEWSWIRE) — Circle8 Group, Inc. (Nasdaq: CIRC) today announced that its Dutch operating company, Circle8 Netherlands, has secured a four-year contract with DUO Groningen, the executive agency of the Dutch Ministry of Education, Culture and Science. The contract has a total value of approximately $314 million over its four-year term.

Under the agreement, Circle8 Netherlands will provide specialist IT expertise supporting DUO’s technology and operational requirements. Eight contractors were deployed at commencement, with the framework providing scope to scale resources over the life of the contract. The agreement commenced May 1, 2026, and runs through April 28, 2030.

The award extends an established relationship between Circle8 Netherlands and DUO and reinforces the Company’s position as a long-term technology and workforce partner to the Dutch public sector. Circle8 Netherlands maintains multi-year mandates across central government, executive agencies, municipalities and regional authorities.

“The renewal with DUO reflects the consistency of our delivery and the trust we have built with important public-sector clients over many years,” said Guus Franke, Chairman and Chief Executive Officer of Circle8 Group. “For Circle8, the significance goes beyond the size of a single contract. Long-duration agreements such as this deepen our customer relationships, strengthen revenue visibility and provide a foundation from which we can expand the technology expertise and higher-value services we deliver across our European platform.”

“DUO’s decision to continue the relationship for another four years is a strong endorsement of the work our teams deliver every day,” said Patrick Schuijt, Chief Revenue Officer of Circle8. “We look forward to continuing to support the organization with the specialist IT capabilities it requires while expanding our contribution as its needs evolve.”

Multi-year public-sector frameworks are an important component of Circle8’s strategy in the Netherlands. These agreements combine long-term customer relationships with the ability to deploy specialized technology talent at scale and create opportunities to broaden the range of services delivered over time.

About Circle8

Circle8 Group, Inc. (Nasdaq: CIRC) is an international technology, workforce and business transformation platform operating across North America and Europe.

Through its portfolio of specialist operating companies, Circle8 delivers technology consulting, artificial intelligence, cybersecurity, cloud, software engineering, engineering, managed services and workforce solutions to enterprise and public-sector organizations. The Company supports clients in designing, building, securing and operating mission-critical technology environments while helping organizations execute complex business and digital transformation programs.

With annualized revenue exceeding US$1.2 billion, more than 16,000 specialists, and operations across North America and Europe, Circle8 is building a scalable platform focused on recurring revenue, higher-value technology services, disciplined acquisitions and long-term shareholder value.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding future growth, recurring revenue, strategic initiatives, acquisitions, customer relationships, market opportunities and business performance. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Readers are encouraged to review the Company’s filings with the U.S. Securities and Exchange Commission for a discussion of these risks and uncertainties. The Company undertakes no obligation to update any forward-looking statements except as required by law.

Investor Contact

Kevin Murphy
Chief Financial Officer
kmurphy@atlantic-international.com

  

Experts in space, quantum technology and cybersecurity will discuss protecting space communications against quantum threats as WISeSat advances the development of orbital infrastructure intended to support the QSOC roadmap.

Geneva, Switzerland / New York, United States — October 7, 2026 — WISeSat.Space Holdings Corp. (NASDAQ: SAIQ) (“WISeSat.Space” or “Company”) today announced that its management team will ring the Nasdaq Opening Bell on Friday, October 9, 2026, celebrating the listing of its ordinary shares on Nasdaq and outlining its strategy to develop trusted, quantum-resilient space communications.

Following the Bell ceremony, WISeSat.Space will organize a Quantum Space Security Roundtable to discuss the technologies, infrastructure and development milestones needed to support this strategy. The event will connect the evolving security requirements of satellite networks with WISeSat.Space’s planned orbital infrastructure and potential customer applications.

October 9 Events:
Location: 151 West 43^rd Street
Nasdaq Opening Bell Ceremony
8:30 a.m. ET | 10:00 a.m. ET
Management Presentation, Roundtable Discussions and Luncheon
10:00 a.m. – 4:00 p.m. ET

The event will bring together leading experts in space, quantum technology and cybersecurity to discuss how satellite communications and their supporting infrastructure can be protected against emerging quantum computing threats.

Carlos Moreira, Founder and CEO of WISeSat.Space noted, “Ringing the Nasdaq Opening Bell is an opportunity to introduce investors to our strategy and the milestones ahead as we work to bring trust and quantum resilience into space infrastructure. By convening leading experts, we want to advance the discussion on how to protect satellite communications throughout their operational lives. Our planned next-generation satellite missions are intended to progressively expend the orbital infrastructure supporting the QSOC roadmap and advance our vision for sovereign, secure and resilient space communications.”

The roundtable will take place in two sessions, both moderated by Mr. Moreira. Further details are available at https://wisesat.space/events/.

The first session, “Space Security and Sovereignty,” will bring together Jessica Rosenworcel, Executive Director of the MIT Media Lab and former Chair of the US Federal Communications Commission; Cristina Dolan, Non-Executive Director of SEALSQ; Liz Hanson, Managing Director, Technology Investment Banking, at KeyBanc Capital Markets; and Mark Minevich, Strategic Partner at Mayfield and President of Going Global Ventures.

The second session, “Building the Secure Space Stack,” will feature Julián Fernández, CEO and Co-founder of FOSSA Systems; Nick Farina, Co-founder and CEO of EeroQ; and, from WISeSat.Space, Philip Hamelink, Interim Head; Gwenael Rouy-Poirier, Chief Financial Officer; and Alex Moreira, Satellite Sales Engineer.

The discussion will address a central challenge: satellites deployed today must remain secure throughout their operational lives as computing capabilities and cyber threats evolve. Participants will explore how to build long-term protection into space infrastructure, from orbital platforms to ground stations and connected user devices.

Bringing hardware-backed trust and post-quantum security into space
The roundtable will examine how post-quantum cryptography, hardware roots of trust, digital identity and secure key management can establish trust across the entire communications chain.

Participants will discuss how these capabilities can complement existing encryption mechanisms by strengthening authentication, protecting cryptographic keys and supporting secure updates throughout a satellite’s operational life.

Experts will also discuss trusted supply chains, interoperability and sovereign control over identities, keys and data, essential foundations for resilient space communications.

Building the orbital infrastructure intended to support QSOC
The event will highlight WISeSat.Space’s role in supporting the planned Quantum Spatial Orbital Cloud (“QSOC”) roadmap. QSOC is a SEALSQ-owned quantum and post-quantum service roadmap expected to leverage WISeSat satellite infrastructure as part of its future orbital layer.

Through planned next-generation satellite missions, WISeSat.Space intends to expand the orbital infrastructure intended to support QSOC and progressively integrate additional security capabilities. Development is expected to advance through successive deployment, testing and validation milestones.

The long-term strategy includes hybrid architectures combining dedicated satellite infrastructure, access to compatible third-party space assets and terrestrial networks, supported by trusted identity and cryptographic technologies. Potential applications include secure IoT connectivity, trusted data exchange and resilient communications for governments, enterprises and critical infrastructure operators.

About WISeSat.Space
WISeSat.Space Holdings Corp. (NASDAQ: SAIQ) is a space technology company focused on secure satellite communications and related space infrastructure. Its approach combines satellite infrastructure with cybersecurity and digital identity technologies to support trusted communications between connected devices and ground-based systems. WISeSat.Space intends to provide satellite capacity and related space and ground infrastructure that may support SEALSQ’s planned QSOC roadmap. Visit wisesat.space⁠.

Forward-looking statements
This communication expressly or implicitly contains certain forward-looking statements concerning WISeSat.Space and its businesses. Forward-looking statements include statements regarding our business strategy, planned satellite launches and missions, development of satellite infrastructure, technology integration, the QSOC roadmap, future services, market opportunities, events or developments that we expect or anticipate will occur in the future, as well as any other statements which are not historical facts.
Although we believe that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates which are inherently subject to significant uncertainties and contingencies, many of which are beyond our control. Actual results may differ materially from those expressed or implied by such forward-looking statements.
Important factors that, in our view, could cause actual results to differ materially from those discussed in the forward-looking statements include WISeSat.Space’s ability to execute its planned satellite deployment and technology-development roadmap, technical validation and integration requirements, launch availability, financing, regulatory approvals, commercial agreements, market demand and the risks discussed in WISeSat.Space’s filings with the SEC. Risks and uncertainties are further described in reports filed by WISeSat.Space with the SEC.
WISeSat.Space is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

CONTACTS

WISeSat:
Carlos Moreira
Chairman & CEO
Tel: +41 22 594 3000
info@wisekey.com

WISeSat Investor Relations:
The Equity Group Inc.
Lena Cati
Tel: +1 212 836-9611
Lena.cati@theequitygroup.com

Company Calls for Consideration of New Regulatory Pathways and Cost Saving of Non-Hallucinogenic Neuroplastogens for Alcohol Use Disorder

Vancouver, Canada, Oct. 07, 2026 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND) (the “Company”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogens for scalable treatment  of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder (“AUD”), today announced that it has submitted recommendations to the U.S. Food and Drug Administration (“FDA”) in response to the agency’s public hearing and request for comments on “Considerations for Potential Future Therapeutic Use of Psychedelic Drugs.”

Under FDA Docket No. FDA-2026-N-7542, Clearmind’s recommendations focus on patient access and the potential future therapeutic use of psychedelic-derived non-hallucinogenic neuroplastogens. The Company highlights its clinical trials at Yale University and Johns Hopkins University, which have generated data suggesting that neuroplastogenic compounds that retain the therapeutic benefits of neuroplasticity enhancement while eliminating the hallucinogenic effects of legacy psychedelics may help mitigate the need for expensive supervised dosing.

Clearmind recommends that the FDA consider new guidance for self-administration, at-home-potential therapies, as well as streamlining regulatory pathways, expanding clinical trial access, leveraging Breakthrough Designation, and other measures intended to help bring urgently needed therapies to market. The Company also calls for additional research and clinical collaborations with the U.S. Department of Veterans Affairs (VA), U.S. Department of War (DoW), and U.S. Department of Health and Human Services (HHS) to help pilot safer, at-home-potential neuroplastogenic candidates for AUD and other indications.

“Clearmind has been dedicating substantial resources and effort to advancing awareness of non-hallucinogenic neuroplastogens and their potential role in addressing significant unmet needs in addiction and mental health,” said Dr. Adi Zuloff-Shani, Chief Executive Officer of Clearmind Medicine. “Our engagement with the U.S. federal government reflects our commitment to contributing to the dialogue around patient access, responsible development, and the potential future use of psychedelic-derived therapies. We believe that continued engagement with federal agencies, alongside rigorous clinical research, is important to advancing new treatment options for patients who currently have limited access to care.”

Clearmind’s latest submission follows a series of recent activities involving the U.S. federal government. In April, the Company welcomed President Trump’s Executive Order, “Accelerating Medical Treatments for Serious Mental Illness,” supporting accelerated review and patient access pathways for certain psychedelic therapies.

In July, Clearmind responded to an HHS Request for Information under the Great American Recovery Initiative, highlighting MEAI and non-hallucinogenic neuroplastogens for AUD. Most recently, on September 14, 2026, Clearmind’s Chief of Global Impact, Mary-Elizabeth Gifford, briefed an FDA-convened federal panel on patient access and insights from the Company’s clinical trials at Yale and Johns Hopkins.

About Clearmind Medicine Inc.

Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.

The Company’s intellectual portfolio currently consists of nineteen patent families, including 32 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Shares of Clearmind are listed for trading on Nasdaq under the symbol “CMND.”

For further information, visit: https://www.clearmindmedicine.com or contact:

Investor Relations
invest@clearmindmedicine.com
www.Clearmindmedicine.com

Forward-Looking Statements:

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the potential future therapeutic use of psychedelic-derived therapies; the potential benefits, characteristics, and treatment applications of its non-hallucinogenic neuroplastogen candidates; the Company’s recommendations submitted to the FDA and other governmental agencies; potential future regulatory developments, clinical trial opportunities, and governmental collaborations; the anticipated progress, enrollment, timing, conduct, results, and outcomes of the Company’s clinical development programs; the potential safety, efficacy, regulatory approval, commercialization, and market acceptance of its product candidates; and the Company’s business strategy, intellectual property activities, objectives, plans, expectations, and future operations. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.

• Panel discussion to explore competitive differentiation as AI reshapes drug discovery and development

TORONTO, Oct. 07, 2026 (GLOBE NEWSWIRE) — NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a clinical intelligence company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today announced that Dr. Joseph Geraci, Founder and Chief Scientific and Technical Officer, will participate in the H.C. Wainwright 3rd Annual AI Based Drug Discovery and Development Virtual Conference, taking place October 8–9, 2026.

Dr. Geraci will join the panel “Design Got Cheap – Where Is the Defensible Moat?”, scheduled for 4:00–5:00 p.m. Eastern Time. Fellow panelists include Peyton Greenside, CEO and Co-founder of BigHat Biosciences, and Jennifer Bath, CEO of MindWalk AI. The discussion will be moderated by Swayampakula Ramakanth, Managing Director at H.C. Wainwright & Co.

The panel’s focus on competitive differentiation is particularly relevant to NetraMark’s approach to clinical development. Its proprietary NetraAI platform is designed to uncover explainable patient subpopulations within the small, heterogeneous datasets common in clinical trials. These insights seek to help sponsors understand differences in treatment response, placebo response and adverse events, informing patient selection and subsequent trial design.

“As AI makes it more efficient to generate drug candidates, a critical challenge remains: understanding which patients are most likely to benefit and how to demonstrate that benefit in a clinical trial,” said Dr. Geraci. “At NetraMark, our differentiated approach allows us to seek extract insights about patient populations that AI generally struggles with. This represents an important defensible moat that will augment AI’s capabilities in this field.”

The virtual conference brings together biotechnology and pharmaceutical companies, institutional investors and industry executives to discuss developments in AI-based drug discovery and development.

To register and view conference information, visit: Conference Registration

For more information on NetraMark and NetraAI, visit www.netramark.com.

About NetraAI
NetraAI is engineered to include focus mechanisms that separate small datasets into explainable and unexplainable subsets. Unexplainable subsets are collections of patients that can lead to suboptimal overfit models and inaccurate insights due to poor correlations with the variables involved. NetraAI uses explainable subsets to derive insights and hypotheses (including factors that influence treatment and placebo responses and adverse events), potentially increasing the likelihood of a clinical trial’s success. Many other AI methods lack these focus mechanisms and assign every patient to a class, often leading to “overfitting,” which drowns out critical information that could have been used to improve a trial’s chance of success.

About NetraMark
NetraMark is focused on being a leader in the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions that are targeted at the biotechnology and pharmaceutical industries. The Company’s product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows NetraMark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that NetraMark can work with much smaller datasets often prevalent in clinical trials, and accurately segment diseases into different types, as well as help to classify patients for sensitivity to drugs and/or efficacy of treatment.

For further details on the Company please see the Company’s publicly available documents filed on the System for Electronic Document Analysis and Retrieval+ (SEDAR+).

Forward-Looking Statements
This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation including statements regarding the potential for insights from NetraAI to help sponsors understand differences in treatment response, placebo response and adverse events, informing patient selection and subsequent trial design and the benefits of NetraMark’s differentiation over other AI tools to create a defensible moat. Forward-looking information can be identified by the use of forward-looking terminology such as “expect”, “likely”, “may”, “will”, “should”, “intend”, “anticipate”, “potential”, “proposed”, “estimate” and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions “may”, “would” or “will” happen, or by discussions of strategy. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact. The forward-looking statements are expectations only and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results of the Company or industry results to differ materially from future results, performance or achievements. Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, NetraMark does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise. New factors emerge from time to time, and it is not possible for NetraMark to predict all such factors.

When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements as set out in the materials we file with applicable Canadian securities regulatory authorities on SEDAR+ at www.sedarplus.com including our Annual Information Form for the year ended September 30, 2025. These risk factors and other factors could cause actual events or results to differ materially from those described in any forward-looking information. The Toronto Stock Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information:
Swapan Kakumanu – CFO | swapan@netramark.com | 403-681-2549

Media Contact:
netramark@ampublicrelations.com

• Traditional Medicare reimbursement supports broader access to non-invasive management options for eligible beneficiaries living with permanent urinary incontinence

MÖLNDAL, Sweden, Oct. 07, 2026 (GLOBE NEWSWIRE) — Wellspect HealthCare today announced that the Surity™ portfolio, including the Surity™ Urinary Management System and Surity™ Female and Male External Catheters, may be covered by traditional Medicare for eligible beneficiaries when medically necessary. This milestone represents an important step in expanding access and reducing barriers to at-home management for people affected by severe urinary incontinence in the U.S.

The Surity™ portfolio provides non-invasive management solutions for individuals living with urinary incontinence and is designed to make everyday urine management more comfortable, discreet and reliable. Coding verification under Healthcare Common Procedure Coding System (HCPCS) codes A6590 for the Surity™ Female and Male External Catheters and E2001 for the Surity™ Urinary Management System supports reimbursement access for beneficiaries who meet applicable coverage criteria.

“Medicare reimbursement for the Surity™ portfolio represents a significant milestone in our efforts to help individuals living with permanent urinary incontinence benefit from modern solutions that can support their day-to-day needs,” said Chris Schlenk, Group Vice President at Wellspect HealthCare. “For eligible beneficiaries with permanent urinary incontinence, newly established Medicare coding may help reduce barriers to care and expand choice in urinary management. This achievement reflects our ongoing commitment to helping individuals and their caregivers in managing important care needs with solutions designed to support comfort, confidence, and independence.”

For the more than 13 million people living with urinary incontinence in the U.S.,ⁱ access to management solutions that address care needs like comfort and rest can have meaningful impact. Traditional Medicare reimbursement access for the Surity™ portfolio helps provide eligible beneficiaries with a new choice, combining gentle suction technology with an intuitive design and features that support quiet operation and odor management, assisting in overnight care and bringing added reassurance to daily routines.

Following the introduction of the Surity™ Female and Male External Catheters earlier in 2026, Wellspect launched the Surity™ Urinary Management System in the United States on August 18, completing the full Surity portfolio. Since its introduction, Surity has become one of the most searched external catheter brands on Google.ⁱⁱ

For additional information* about Surity™, including traditional Medicare coverage requirements and eligibility, visit www.surity.care, where you can also connect with a Wellspect Reimbursement Specialist.

*Whether a product or service is covered by traditional Medicare depends on individual situations and Medicare’s requirements. Coverage, coding, and payment decisions are made by individual payers and may vary. Wellspect HealthCare does not guarantee coverage or reimbursement and is not responsible for payer determinations.

Contact Information Investors:

Wade Moody
Senior Manager, Investor Relations
Investorrelations@dentsplysirona.com

Contact Information Press:

Marion Par-Weixlberger
Vice President, Public Relations, Corporate Communications & Brand
Publicrelations@dentsplysirona.com

About Wellspect HealthCare

Wellspect HealthCare, a subsidiary of Dentsply Sirona (NASDAQ: XRAY) is a leading global provider of innovative medical devices dedicated to improving the quality of life for individuals with bladder and bowel dysfunction.

With approximately 1,200 employees worldwide, Wellspect is committed to making a real difference for people managing continence care needs, empowering them to live each day to the fullest.

Wellspect delivers solutions that support safe bladder and bowel management, while continuously enhancing the experience, clinical performance, and service quality for both healthcare professionals and the people in their care.

As one of the world’s leading manufacturers of intermittent urinary catheters, Wellspect has been at the forefront of innovation since 1983 with its LoFric® brand, which introduced the first hydrophilic-coated catheter.

Wellspect has also pioneered the development of Navina™, an innovative transanal irrigation system designed to support individuals living with chronic bowel disorders.

With advanced Surity™, Wellspect provides reliable urinary incontinence care designed to restore comfort, rest, and confidence for people living with severe urinary incontinence and for their caregivers.

Every day, Wellspect strives to maintain the highest quality standards while minimizing the environmental impact of its products.

Headquartered in Mölndal, Sweden, Wellspect operates in more than 40 countries, offering life-enhancing solutions to people around the world. Dentsply Sirona, the world’s largest diversified manufacturer of professional dental products and technologies, is listed on Nasdaq under the symbol XRAY.

_____________________________
ⁱ Leslie SW, Tran LN, Puckett Y. Urinary Incontinence. [Updated 2024 Aug 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK559095/
ⁱⁱ Google Trends. External Catheter Brands. USA; 2026.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/962344d1-fb85-481b-a8e9-201183fbd79a

HMS Networks AB (publ) will release its third quarter report of 2026 on Wednesday October 21^st, 2026, at 07.30 CEST.

On the same day, at 09.00 CEST, President and CEO Staffan Dahlström and CFO Joakim Nideborn present the report in a conference call for press and analysts.

The presentation is in English and can be followed live via telephone or web. Slides used in the presentation will be made available on HMS’ website prior to the telephone conference.

If you wish to participate via webcast, please use the link below.

Link to webcast

If you wish to participate via teleconference, please register on the link below. After registration you will be provided with phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.

Link to teleconference

The presentation and recording of the telephone conference will be available on HMS’ website after the call.

For more information, please contact:
Staffan Dahlström, CEO HMS, +46 (0)35 17 29 01
Joakim Nideborn, CFO HMS, +46 (0)35 710 69 83

HMS Networks AB (publ) is a market-leading provider of solutions in Industrial Information and Communication Technology (Industrial ICT) and employs over 1,100 people. Local sales and support are handled through over 20 sales offices all over the world, as well as through a wide network of distributors and partners. HMS reported sales of SEK 3,577 million in 2025 and is listed on the NASDAQ OMX in Stockholm in the Large Cap segment and Telecommunications sector.

Attachment

• HMS Invitation to the third quarter 2026 conference call

Employees recognize the need to reskill, but managers need stronger tools and organizational support to help people keep pace

NEW YORK, Oct. 07, 2026 (GLOBE NEWSWIRE) — Employers face a growing workforce risk as employees struggle to understand which skills they need and how to develop them quickly enough to keep pace with changing work, according to WTW’s latest EX Intelligent report.

The proportion of employees who say their manager helps develop their abilities has shifted from 84% to 78% over the past four years, highlighting the need to give managers more support for development conversations. At the same time, only about 30% of organizations have established processes for identifying, assessing and tracking workforce skills.

This mismatch risks creating “capability anxiety”: uncertainty among employees about whether their skills will remain relevant, what capabilities will matter most and where they should focus their development.

Employees understand that work is changing. 45% say AI is already important to their daily job and another 22% say it will fundamentally change their work in the future. The pressure point is not change itself, but rather the uncertainty of whether they can keep up, what skills matter most and where to focus next.

Jill Havely, Global Employee Experience Leader at WTW, said: “Employees recognize that work is evolving, but many lack clarity on what skills matter most and how to prepare for what comes next. Without that visibility, uncertainty can become a barrier to confidence and growth.”

“To address this, employers need to make development more tangible by equipping managers to have meaningful career conversations, creating clearer visibility into skills and career opportunities, and linking learning directly to the work employees do every day.”

For organizations, skills uncertainty can create a blind spot. If employees cannot connect their current role with future opportunities, confidence may erode, adaptability may slow and investment in new technology may fail to translate into stronger performance.

WTW recommends that employers:

• identify the skills required to deliver current and future business priorities;
• give employees clearer visibility of career pathways, learning opportunities and internal roles;
• equip managers to discuss changing skill requirements and guide development; and
• use employee listening and workforce data to identify where uncertainty or capability gaps may be affecting confidence and performance.

Havely added: “Workforce transformation is more likely to succeed when employees can see a clear path to growth and organizations have the infrastructure to support it. By making skills, career pathways and development opportunities more visible and actionable, employers can reduce capability anxiety and build a workforce better equipped to adapt, grow and perform.”

About the research

WTW’s 2026 Employee Experience Global Market Study includes responses from 549 employer organizations representing 5.6 million employees globally. It also draws on insights from 7,000 employees across the United States, United Kingdom, Japan, France and Saudi Arabia.

About WTW

At WTW, we provide data-driven, insight-led solutions in the areas of people, risk and capital. Leveraging the global view and local expertise of our colleagues serving 140 countries and markets, we help organizations sharpen strategy, enhance organizational resilience, motivate their workforce and maximize performance. Working shoulder to shoulder with clients, we uncover opportunities for sustainable success — and provide perspective that moves you.

Media contacts

Arnelle Sullivan

Arnelle.Sullivan@wtwco.com

Ileana Feoli

Ileana.Feoli@wtwco.com